An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

Nathwani, Dilip; Li, Jim Z.; Balan, Dan A; Willke, Richard J.; Rittenhouse, B; Mozaffari, Essy; Tavakoli, Manouche; Tang, Tom

doi:10.1016/j.ijantimicag.2003.09.020

Cited by 19 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipophilicity can play a major role in the pharmacokinetic profile of a drug because it can affect the distribution, binding affinities and elimination properties of the drug. Based on this, it was postulated that a teicoplanin preparation with a lower proportional content of subcomponents that have a longer half-life, like A 2-4 and A [2][3][4][5] , and a higher proportion of those with a shorter half-life, like A 2-1 and A 2-2 , would have more rapid overall elimination, and the resulting AUC would be decreased. 12 If this is the case, the opposite would also be true, i.e.…”

Section: Resultsmentioning

confidence: 99%

“…Of these, methicillinresistant S. aureus (MRSA) is particularly problematic from a treatment perspective, owing to its multidrug-resistant nature. 2 Teicoplanin is an effective treatment option against antibioticresistant Gram-positive bacteria, like MRSA, and is reserved for pharmacotherapeutical interventions in cases of drug-resistant septicaemia, endocarditis, and infections of the skin and soft tissue, bone and joints, and the lower respiratory tract. A number of advantages are associated with the use of teicoplanin over other currently available glycopeptides.…”

Section: Introductionmentioning

confidence: 99%

“…3 Teicoplanin is a glycopeptide antibiotic, a class which includes vancomycin, telavancin, bleomycin and ramoplanin. The pharmacologically active ingredient, teicoplanin, refers to a group of structurally similar chemical entities, termed teicoplanin A 2-1 to A [2][3][4][5] , which are microbial secondary metabolites produced by a number of non-ribosomal peptide synthetases to form a cyclic heptapeptide structure. The A 2-1 to A 2-5 structural forms account for 89-95% of active teicoplanin.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation

Greeff

Tonder

Cromarty

et al. 2015

Southern African Journal of Infectious Diseases

View full text Add to dashboard Cite

Introduction:Teicoplanin is an effective treatment option against methicillin-resistant, Gram-positive bacteria, like Staphylococcus aureus. It is a glycopeptide antibiotic, produced through microbial fermentation, a process resulting in variations in the N-acyl side chain. Concerns that these variations may affect the pharmacokinetic profile and the clinical efficacy of generic teicoplanin preparations have been raised. Method: To address this issue, a multi-centre observational study was conducted to evaluate steady-state peak and trough serum concentrations, and the serum bactericidal activity (SBA) and safety of a generic teicoplanin preparation in critically ill patients. Additionally, the composition of the generic teicoplanin was compared to that of the innovator drug to assess differences in the composition. Results: Following pre-determined loading and maintenance dose schedules, the mean peak and trough teicoplanin serum concentrations were 20.98 mg/l and 10.38 mg/l, respectively. A statistically significant association was observed between teicoplanin pharmacotherapy and increased ex vivo SBA. It was found using independent analysis that the composition of the generic teicoplanin preparation was similar to that of the innovator drug, and that both formulations met the European Pharmacopoeia specifications. Conclusion:The loading and maintenance schedules employed in this study were effective in establishing therapeutic serum teicoplanin concentrations in critically ill patients. Evidence of bactericidal activity measured in patients' ex vivo serum samples, following treatment with the generic preparation, supports this finding.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation

Greeff

Tonder

Cromarty

et al. 2015

Southern African Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Previous economic studies have demonstrated that linezolid was more cost-effective than teicoplanin in treating MRSA infections [45,46]. This may be due to linezolid's higher efficacy and fewer days of hospital stay, leading to a reduction in the total duration of hospital stay, treatment and costs.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis

Chen

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of serious infections. Linezolid and teicoplanin are widely used in the treatment of infections caused by MRSA. However, the efficacy and safety of linezolid compared with teicoplanin remains controversial. The purpose of this study was to systematically review the efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections. Methodology: A meta-analysis was performed on the published studies. Pooled relative risk (RR) and 95% confidence interval (95% CI) were calculated to determine whether there were significant differences between the linezolid group and the teicoplanin group on the efficacy and safety. Results: Seventeen studies were included, involving 2,040 patients. The results showed that linezolid was associated with better clinical cure rate (RR = 1.14, 95% CI = 1.08-1.21, p < 0.00001) and microbiological eradication rate (RR = 1.28, 95% CI = 1.18-1.39, p < 0.00001) compared with teicoplanin. There were no statistically significant differences between the two groups in the treatment of MRSA infections regarding the adverse events (RR = 1.15, 95% CI = 0.97-1.35, p = 0.10) and the mortality (RR = 0.85, 95% CI = 0.61-1.18, p = 0.33). Conclusions: The results suggest that linezolid may be a better choice for the treatment of patients with MRSA infections. However, our recommendation is that the decision about treating MRSA infections with linezolid or with teicoplanin should depend on local availability, patient population, dosage regimens, costs and safety, rather than presumed differences in efficacy.

show abstract

“…Additionally, it has demonstrated greater effectiveness than other antibiotics in selected indications [12][13][14][15][16] and less consumption of healthcare resources 17,18 .…”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

et al. 2005

View full text Add to dashboard Cite

show abstract

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

Cited by 19 publications

References 38 publications

A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation

A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation

Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis

Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

Contact Info

Product

Resources

About